End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.8 TWD | +1.42% | -0.58% | -34.25% |
03-14 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-06 | Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer | CI |
Business Summary
Sales per Business
TWD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceuticals
100.0
%
| 22 | 100.0 % | 61 | 100.0 % | +174.11% |
Sales per region
TWD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Taiwan
87.4
%
| 22 | 100.0 % | 54 | 87.4 % | +139.70% |
United States
12.6
%
| 0 | 0.0 % | 8 | 12.6 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kuan Hao Lin
DFI | Director of Finance/CFO | - | 22-02-17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
ALLEN Chao
FOU | Founder | 78 | 13-05-07 |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-10-05 |
Chih Chuan Chen
BRD | Director/Board Member | - | 13-10-05 |
Tai Chang Wang
BRD | Director/Board Member | 65 | 21-08-26 |
Chin Pao Tsai
BRD | Director/Board Member | - | 15-05-14 |
Lin Zheng Chen
CEO | Chief Executive Officer | - | 15-05-14 |
Cheng Hsia
BRD | Director/Board Member | - | 15-05-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 164,026,867 | 98,110,867 ( 59.81 %) | 0 | 59.81 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-34.25% | 214M | |
+7.52% | 111B | |
+11.31% | 106B | |
-12.18% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.92% | 16.81B | |
+38.60% | 12.54B | |
-24.44% | 8.09B |
- Stock Market
- Equities
- 6541 Stock
- Company Tanvex BioPharma, Inc.